James C Shaw1, Lucile E White. 1. Division of Dermatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada. jc.shaw@utoronto.ca
Abstract
BACKGROUND: Spironolactone has been used for over 20 years as an antiandrogen in the treatment of acne and hirsutism. No long-term studies of the safety of spironolactone used in this manner have been published. We present a study of the long-term safety and tolerance of spironolactone in 91 women with acne who were followed for up to 8 years. METHODS: A survey questionnaire was sent to 210 patients, and a comparison chart review of all patients to whom the survey was sent was made. RESULTS: Ninety-one completed surveys were analyzed, comprising 506 person-years of followup and 200 person-years of spironolactone exposure. Mean treatment length was 28.5 months (range = 0.5-122 months). During the 8-year followup period, there were no cases of serious illness attributable to spironolactone use. Side effects were present in 59% and resulted in cessation of the drug in 15%. Diuretic effect and menstrual irregularities were the most common adverse effects. CONCLUSIONS: After 200 person-years of exposure to spironolactone and 506 person-years of followup over 8 years, no serious illnesses thought to be attributed to spironolactone were reported. The long-term use of spironolactone in the treatment of acne in women appears to be safe. Side effects, however, are common, although not usually a cause for stopping the drug.
BACKGROUND:Spironolactone has been used for over 20 years as an antiandrogen in the treatment of acne and hirsutism. No long-term studies of the safety of spironolactone used in this manner have been published. We present a study of the long-term safety and tolerance of spironolactone in 91 women with acne who were followed for up to 8 years. METHODS: A survey questionnaire was sent to 210 patients, and a comparison chart review of all patients to whom the survey was sent was made. RESULTS: Ninety-one completed surveys were analyzed, comprising 506 person-years of followup and 200 person-years of spironolactone exposure. Mean treatment length was 28.5 months (range = 0.5-122 months). During the 8-year followup period, there were no cases of serious illness attributable to spironolactone use. Side effects were present in 59% and resulted in cessation of the drug in 15%. Diuretic effect and menstrual irregularities were the most common adverse effects. CONCLUSIONS: After 200 person-years of exposure to spironolactone and 506 person-years of followup over 8 years, no serious illnesses thought to be attributed to spironolactone were reported. The long-term use of spironolactone in the treatment of acne in women appears to be safe. Side effects, however, are common, although not usually a cause for stopping the drug.
Authors: Katarzyna Mleczko-Sanecka; Ana Rita da Silva; Debora Call; Joana Neves; Nikolai Schmeer; Georg Damm; Daniel Seehofer; Martina U Muckenthaler Journal: Haematologica Date: 2017-04-06 Impact factor: 9.941
Authors: Alison M Layton; E Anne Eady; Heather Whitehouse; James Q Del Rosso; Zbys Fedorowicz; Esther J van Zuuren Journal: Am J Clin Dermatol Date: 2017-04 Impact factor: 7.403